Pharmaceutical composition and use
Patent 5317022 Issued on May 31, 1994. Estimated Expiration Date: 
October 2, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
October 2, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesOximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists Patent #: 4889860 Inventors
AssigneeApplicationNo. 934547 filed on 10/02/1992US Classes:514/282One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)ExaminersPrimary: Waddell, Frederick E.Assistant: Hook, Gregory Attorney, Agent or FirmForeign Patent References
International ClassA61K 031/114Foreign Application Priority Data1991-02-04 HUAbstractA biologically active preparation for human or veterinary use for the selective blockade of opioid binding sites of the brain responsible for respiratory depression containing in a biologically active quantity the codeinone derivative of general formula (I) or its saltR1 means amino--, hydroxyl--, --NH--phenyl or --NH--CO--NH2 groups,R2 means a hydrogen atom or a hydroxyl group.The invention also covers a process for selective blocking the opioid binding sites of the brain responsible for respiratory depression by administering to a patient in need of an analgetic a preparation containing a codeinone derivative of general formula (I) or its salt preferably three times per day in doses of 2,5-5 mg.A preferred feature of the inventions is an analgetic composition containing a codeinone derivative of general formula (I) and in a mass ratio of 1 : 2-3 morphine of the formula (IV) or an other, biologically equipotent agonist type opiate or opioid compound and optionally inert, pharmaceutically acceptable accompanying materials.Other References
| |
